Dr. Bruce Patterson Talks about COVID-19

Today we will discuss the following topics with Dr. Bruce Patterson:
1. Long haulers-cytokine storm going to cytokine heavy rainfall!
2. Virologic vs immunologic phases-what does it mean for the clinicians
3. Role of CCL5/RANTES
4. Implications of Plasma viral load
5. Leronlimab MOA and role in COVID

Itolizumab: CD6 and Pan T Cell suppressor. Reduces cytokines. And, T cell activation.

Lenzilumab: that targets colony stimulating factor 2 (CSF2)/granulocyte-macrophage colony stimulating factor (GM-CSF).

PRO 140 (leronlimab) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system.

Itolizumab
https://en.wikipedia.org/wiki/Itolizumab

Lenzilumab
https://en.wikipedia.org/wiki/Lenzilumab

Leronlimab
https://en.wikipedia.org/wiki/PRO_140

Dr. Bruce Patterson
https://incelldx.com/who-we-are/

Dr. Patterson received his undergraduate training in molecular biology from the University of Michigan in Ann Arbor. He then went on to Northwestern University Medical School for training in medicine. During the early stages of the AIDS epidemic, Dr. Patterson began investigating cellular reservoirs of HIV-1 using molecular and in situ technology patented in his laboratory. Dr. Patterson went on to a residency in Pathology focusing on viral pathogenesis. While in his residency, Dr. Patterson determined that enough HIV virus was present in infected individuals to account for the massive destruction of the immune system. This paradigm altering work was published in Science in 1993. Dr. Patterson later was named Chief Resident of Pathology at Northwestern Memorial Hospital. Dr. Patterson has authored over 100 manuscripts and book chapters and he continues his work on HIV-1 pathogenesis and reservoirs at Stanford University School of Medicine. Dr. Patterson was the Medical Director of Diagnostic Virology at Stanford University Hospitals and Clinics.